NASDAQ
IMRN

Immuron Ltd ADR

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Immuron Ltd ADR Stock Price

Vitals

Today's Low:
$1.7301
Today's High:
$1.94
Open Price:
$1.87
52W Low:
$1.39
52W High:
$3.21
Prev. Close:
$1.95
Volume:
2283

Company Statistics

Market Cap.:
$11.11 million
Book Value:
3.44
Revenue TTM:
$1.80 million
Operating Margin TTM:
-188.89%
Gross Profit TTM:
$1.74 million
Profit Margin:
-209.81%
Return on Assets TTM:
-9.1%
Return on Equity TTM:
-17.7%

Company Profile

Immuron Ltd ADR had its IPO on 2017-06-09 under the ticker symbol IMRN.

The company operates in the Healthcare sector and Biotechnology industry. Immuron Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of Immuron Ltd ADR opened at $1.87 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.73 - $1.94, and closed at $1.94.

This is a -0.51% slip from the previous day's closing price.

A total volume of 2,283 shares were traded at the close of the day’s session.

In the last one week, shares of Immuron Ltd ADR have increased by +4.3%.

Immuron Ltd ADR's Key Ratios

Immuron Ltd ADR has a market cap of $11.11 million, indicating a price to book ratio of 0.7383 and a price to sales ratio of 15.4352.

In the last 12-months Immuron Ltd ADR’s revenue was $1.80 million with a gross profit of $1.74 million and an EBITDA of $-3404228. The EBITDA ratio measures Immuron Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Immuron Ltd ADR’s operating margin was -188.89% while its return on assets stood at -9.1% with a return of equity of -17.7%.

In Q2, Immuron Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 128.6%.

Immuron Ltd ADR’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Immuron Ltd ADR’s profitability.

Immuron Ltd ADR stock is trading at a EV to sales ratio of 0.4132 and a EV to EBITDA ratio of 0.888. Its price to sales ratio in the trailing 12-months stood at 15.4352.

Immuron Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$23.10 million
Total Liabilities
$1.68 million
Operating Cash Flow
$2078.00
Capital Expenditure
$3642
Dividend Payout Ratio
0%

Immuron Ltd ADR ended 2024 with $23.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.10 million while shareholder equity stood at $21.26 million.

Immuron Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $1.68 million in other current liabilities, 88436263.00 in common stock, $-70403664.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.48 million and cash and short-term investments were $19.14 million. The company’s total short-term debt was $35,160 while long-term debt stood at $0.

Immuron Ltd ADR’s total current assets stands at $20.33 million while long-term investments were $1.83 million and short-term investments were $668752.00. Its net receivables were $344058.00 compared to accounts payable of $121699.00 and inventory worth $495642.00.

In 2024, Immuron Ltd ADR's operating cash flow was $2078.00 while its capital expenditure stood at $3642.

Comparatively, Immuron Ltd ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.94
52-Week High
$3.21
52-Week Low
$1.39
Analyst Target Price
$

Immuron Ltd ADR stock is currently trading at $1.94 per share. It touched a 52-week high of $3.21 and a 52-week low of $3.21. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $1.98 and 200-day moving average was $2.02 The short ratio stood at 8.7 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 162.9% are held by institutions.

Frequently Asked Questions About Immuron Ltd ADR

The stock symbol (also called stock or share ticker) of Immuron Ltd ADR is IMRN

The IPO of Immuron Ltd ADR took place on 2017-06-09

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$16.73
0.51
+3.14%
$2.57
-0.01
-0.39%
$199.35
-15.5
-7.21%
$4.09
0.06
+1.49%
$1226.85
-88.9
-6.76%
$332.5
-17.9
-5.11%
$1.2
0
+0.42%
$1.05
0
0%
$107.89
1.06
+0.99%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers’ diarrhea in the United States, and Phase II field trial for Travelers’ Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Address

62 Lygon Street, Carlton, VIC, Australia, 3053